Quick Links: Skip to main page content Skip to Search Skip to Topics Menu Skip to Common Links
  • Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Pediatric Studies Characteristics - Detail
  • Print
  • Share
  • E-mail
-
 
Approval Date:  05/28/2009
 
Trade Name:  Besivance
 
Generic or Proper Name (*):  besifloxacin ophthalmic suspension
 
Indications Studied:  Treatment of bacterial conjunctivitis
 
Therapeutic Category:  Antibiotic, topical
 
Ages Studied:  1 year and older
 
Study #:  3
 
Study Type:  Efficacy/Safety
 
Study Design:  Single-Blind/Active Control/Parallel Group
 
No Patients:  331
 
No Centers:  84
 
No Countries:  3
 
BPCA(B), PREA(P):  P
 
-
-